|1.||Reboli, Annette C: 10 articles (01/2014 - 02/2007)|
|2.||Walsh, Thomas J: 9 articles (02/2012 - 09/2004)|
|3.||Guarro, Josep: 7 articles (08/2015 - 06/2008)|
|4.||Mayayo, Emilio: 6 articles (08/2015 - 03/2011)|
|5.||Kett, Daniel H: 6 articles (01/2014 - 06/2007)|
|6.||Liu, Ping: 5 articles (08/2014 - 02/2012)|
|7.||Pappas, Peter G: 5 articles (01/2014 - 10/2003)|
|8.||Goldstein, Beth P: 5 articles (07/2008 - 06/2004)|
|9.||Schlamm, Haran T: 4 articles (01/2014 - 01/2011)|
|10.||Hope, William W: 4 articles (10/2012 - 06/2009)|
06/01/2008 - "We have reviewed the existing data on the efficacy of anidulafungin, which is the most recent echinocandin in the experimental treatment of fungal infections. "
10/01/2011 - "Antifungal prophylaxis with anidulafungin has proven effective and has presented no significant adverse effects on a patient at high risk of fungal infection and multiple risk factors for drug interactions."
01/01/2011 - "Anidulafungin was associated with significantly faster clearance of blood cultures (log-rank p < 0.05) and significantly fewer persistent infections (2.7% vs 13.1%; p < 0.05). "
01/01/2009 - "Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections. "
01/01/2009 - "Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections."
01/01/2009 - "Results of several clinical trials indicate that anidulafungin is effective in treating oesophageal candidiasis, including azole-refractory disease. "
07/15/2006 - "Results of several clinical trials indicate that anidulafungin is effective in treating esophageal candidiasis, including azole-refractory disease. "
07/01/2008 - "A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis."
08/01/2009 - "Our data suggest that the efficacy of anidulafungin in the treatment of candidiasis might stem from both direct fungicidal activity and indirect PAFEs that lessen the ability of Candida cells to establish invasive disease and to persist within infected hosts."
07/01/2008 - "We performed an open-label, noncomparative study to examine efficacy and safety of anidulafungin in patients with azole-refractory oropharyngeal and esophageal candidiasis. "
12/01/2010 - "Anidulafungin was effective in the treatment of patients with documented candidemia arising from different sites, and no significant side effects were observed."
11/01/2005 - "In a phase 2 open-label, dose-ranging study in patients with candidemia, anidulafungin was effective in eradicating Candida albicans and other species of Candida. "
01/01/2013 - "Anidulafungin has been reported to be an effective treatment for candidemia in Western populations, but little is known about its efficacy in Asian patients, where the clinical presentation and epidemiology may be different. "
11/01/2006 - "This pharmacokinetic-pharmacodynamic picture of anidulafungin persistence in tissues and the resultant persistent fungal decline should be exploited to improve the efficacy of anidulafungin therapy for candidemia."
01/01/2013 - "An open-label study of anidulafungin for the treatment of candidemia was recently conducted in several Asian countries. "
06/01/2004 - "The clearance of anidulafungin was influenced by weight and gender, and subjects in the invasive candidiasis study had a typical clearance that was approximately 30% higher than subjects from other studies. "
01/01/2003 - "In January 2003, Versicor announced that positive results from a phase II trial for anidulafungin IV treatment involving 120 patients in the US with invasive candidiasis/candidaemia, have led to another double-blind, randomised phase III trial being conducted in the US, Canada and Europe for this indication. "
06/01/2013 - "In addition, we demonstrated anidulafungin efficacy in treating biofilm-related invasive candidiasis."
10/01/2011 - "Anidulafungin was mostly used for pre-emptive (69%) and first-line treatment (17%) of invasive candidiasis. "
01/01/2014 - "An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America."
01/01/2007 - "After promising results from animal models, the role of anidulafungin in the treatment of invasive aspergillosis and other filamentous fungi is yet to be cleared. "
09/01/2004 - "Although the activity of anidulafungin in animal models of pulmonary or disseminated aspergillosis shows increased survival and improvement in the pulmonary infarct score, the effect on residual fungal burden and Aspergillus antigenemia determination does not indicate in vivo fungicidal activity. "
01/01/2013 - "Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis."
02/01/2008 - "On the other hand, there is insufficient evidence as of yet to support first-line use of anidulafungin in patients with neutropenia or aspergillosis."
12/01/2000 - "The efficacy of ravuconazole, a new triazole antifungal agent, and the echinocandin LY-303366 were evaluated in an immunosuppressed, temporarily leukopenic rabbit model of invasive aspergillosis. "
|6.||Amphotericin B (Amphotericin)
|8.||ER 30346 (ravuconazole)
|4.||Transplantation (Transplant Recipients)